Home
Life Sciences

Sector: Life Sciences

Janssen’s latest move against Amgen highlights shifting pharma patent strategies

J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition

Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion

The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect

Life Sciences correspondent

Thought leadership from industry experts

Latest content

Exploring third-party claims in pharmaceutical patent cases

What are the rights of public healthcare providers and companies seeking damages in the United Kingdom, the Netherlands, France and Norway?

19 October 2022

EPO’s Enlarged Board of Appeal hints at surprising decision on plausibility

Forum considering whether and when post-filed evidence can be relied upon for purposes of plausibility

18 October 2022

Top patentee jury verdicts from US courts in the third quarter

Here’s a look at the data about the rights’ holders and dollar sums behind the 31 patent damages awards from 1 July to 30 September

17 October 2022

SCOTUS gives Gilenya generics the green light in fresh blow to Novartis

The move is latest setback for the patentee in its dramatic written description dispute

17 October 2022

EU’s Teva patent abuse allegations reflect growing competition law scrutiny of IP strategies

The European Commission has preliminarily found that the Israeli company has broken antitrust rules

11 October 2022

Amgen’s in-house litigators secure good results in ANDA patent litigation

Docket Navigator shows that Amgen’s in-house legal team appeared on 78 of the 85 patent assertions in US district court since 2008

10 October 2022

Five SCOTUS developments that life sciences IP professionals need to know about

The past two weeks have seen a flurry of patent-related activity at the US Supreme Court

07 October 2022

SCOTUS signals willingness to tackle skinny label questions worrying generic drug industry

The Supreme Court's request for Solicitor General input increases the chances of a hearing on skinny-label controversies

06 October 2022

Waco jury awards $273 million damages in first battle of David-v-Goliaths licensing campaign

Ravgen is pursuing several large diagnostics companies in patent enforcement drive

04 October 2022

Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker

Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market

03 October 2022

Unlock unlimited access to all IAM content